MITOXANTRONE |
NSC-279836 |
MITOXANTRONE HCL |
NOVANTRONE |
CL-232315 |
MITOXANTRONUM |
NOVANTRONEĀ® |
1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE |
MITOXANTRONA |
pubchem.compound:4212 |
drugbank:01204 |
rxcui:7005 |
chembl:CHEMBL58 |
chemidplus:65271-80-9 |
Drug Categories | anthraquinones |
Drug Categories | anthracenes |
Drug Class | antineoplastic agents |
Year of Approval | 1987 |
Drug Class | Small molecule |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | antineoplastic agent |
Drug Categories | cardiotoxic antineoplastic agents |
Drug Categories | cytochrome p-450 cyp2e1 inducers |
Drug Categories | cytochrome p-450 cyp2e1 inducers (strength unknown) |
Drug Categories | cytochrome p-450 cyp2e1 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 enzyme inducers |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | p-glycoprotein inducers |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | p-glycoprotein substrates with narrow therapeutic index |
inhibitor (inhibitory) |
Direct Interaction? | False |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
MITOXANTRONE | DrugBank Drug Name |
65271-80-9 | CAS Number |
Mitoxantrone | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
MITOXANTRONE | Primary Drug Name |
Year of Approval | 1987 |
Drug Class | antineoplastic agents |
Drug Indications | antineoplastic agent |
Drug Class | Small Molecule |
FDA Approval | approved |
CHEMBL58 | ChEMBL Drug ID |
C665 | NCI drug code |
MITOXANTRONE | GuideToPharmacology Ligand Name |
D0R3JB | TTD Drug ID |